argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia

"argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it has recruited 50% of the immune thrombocytopenia (ITP) patients in the Phase 2 proof-of-concept study of ARGX-113.

“We are pleased to have reached the 50% recruitment milestone in this study, which is enrolling on schedule,” commented Nicolas Leupin, Chief Medical Officer of argenx. “We remain on track, and look forward to presenting top-line data from the ARGX-113 clinical trial in ITP in the second half of 2018, which will be our second indication with Phase 2 top-line data from ARGX-113.”"

- From argenx press release

Read More

back to top
Charity Navigator
GuideStar Seal
NORD Member Badge
THSNA logo
THSNA Summit 2024
April 3-6th